186 related articles for article (PubMed ID: 23909965)
1. Efficacy of increasing donepezil in mild to moderate Alzheimer's disease patients who show a diminished response to 5 mg donepezil: a preliminary study.
Yatabe Y; Hashimoto M; Kaneda K; Honda K; Ogawa Y; Yuuki S; Ikeda M
Psychogeriatrics; 2013 Jun; 13(2):88-93. PubMed ID: 23909965
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
3. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.
Jones RW; Soininen H; Hager K; Aarsland D; Passmore P; Murthy A; Zhang R; Bahra R
Int J Geriatr Psychiatry; 2004 Jan; 19(1):58-67. PubMed ID: 14716700
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study.
Boada-Rovira M; Brodaty H; Cras P; Baloyannis S; Emre M; Zhang R; Bahra R;
Drugs Aging; 2004; 21(1):43-53. PubMed ID: 14715043
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group.
Homma A; Takeda M; Imai Y; Udaka F; Hasegawa K; Kameyama M; Nishimura T
Dement Geriatr Cogn Disord; 2000; 11(6):299-313. PubMed ID: 11044775
[TBL] [Abstract][Full Text] [Related]
6. Donepezil in the treatment of mild to moderate Alzheimer's disease: report of a Belgian multicenter study.
Santens P; Ventura M
Acta Neurol Belg; 2003 Sep; 103(3):159-63. PubMed ID: 14626696
[TBL] [Abstract][Full Text] [Related]
7. Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic.
Matthews HP; Korbey J; Wilkinson DG; Rowden J
Int J Geriatr Psychiatry; 2000 Aug; 15(8):713-20. PubMed ID: 10960883
[TBL] [Abstract][Full Text] [Related]
8. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease.
Krishnan KR; Charles HC; Doraiswamy PM; Mintzer J; Weisler R; Yu X; Perdomo C; Ieni JR; Rogers S
Am J Psychiatry; 2003 Nov; 160(11):2003-11. PubMed ID: 14594748
[TBL] [Abstract][Full Text] [Related]
9. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease.
Wilcock G; Howe I; Coles H; Lilienfeld S; Truyen L; Zhu Y; Bullock R; Kershaw P;
Drugs Aging; 2003; 20(10):777-89. PubMed ID: 12875613
[TBL] [Abstract][Full Text] [Related]
10. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.
Feldman H; Gauthier S; Hecker J; Vellas B; Subbiah P; Whalen E;
Neurology; 2001 Aug; 57(4):613-20. PubMed ID: 11524468
[TBL] [Abstract][Full Text] [Related]
11. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease.
Doody RS; Geldmacher DS; Gordon B; Perdomo CA; Pratt RD;
Arch Neurol; 2001 Mar; 58(3):427-33. PubMed ID: 11255446
[TBL] [Abstract][Full Text] [Related]
12. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials.
Whitehead A; Perdomo C; Pratt RD; Birks J; Wilcock GK; Evans JG
Int J Geriatr Psychiatry; 2004 Jul; 19(7):624-33. PubMed ID: 15254918
[TBL] [Abstract][Full Text] [Related]
13. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.
Rogers SL; Farlow MR; Doody RS; Mohs R; Friedhoff LT
Neurology; 1998 Jan; 50(1):136-45. PubMed ID: 9443470
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study.
Rogers SL; Friedhoff LT
Eur Neuropsychopharmacol; 1998 Feb; 8(1):67-75. PubMed ID: 9452942
[TBL] [Abstract][Full Text] [Related]
15. Donepezil: a review of its use in Alzheimer's disease.
Dooley M; Lamb HM
Drugs Aging; 2000 Mar; 16(3):199-226. PubMed ID: 10803860
[TBL] [Abstract][Full Text] [Related]
16. A large, community-based, open-label trial of donepezil in the treatment of Alzheimer's disease.
Relkin NR; Reichman WE; Orazem J; McRae T
Dement Geriatr Cogn Disord; 2003; 16(1):15-24. PubMed ID: 12714795
[TBL] [Abstract][Full Text] [Related]
17. Donepezil use in Alzheimer disease.
Barner EL; Gray SL
Ann Pharmacother; 1998 Jan; 32(1):70-7. PubMed ID: 9475825
[TBL] [Abstract][Full Text] [Related]
18. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study.
Aarsland D; Laake K; Larsen JP; Janvin C
J Neurol Neurosurg Psychiatry; 2002 Jun; 72(6):708-12. PubMed ID: 12023410
[TBL] [Abstract][Full Text] [Related]
19. Donepezil: an anticholinesterase inhibitor for Alzheimer's disease.
Shintani EY; Uchida KM
Am J Health Syst Pharm; 1997 Dec; 54(24):2805-10. PubMed ID: 9428950
[TBL] [Abstract][Full Text] [Related]
20. EEG changes during long-term treatment with donepezil in Alzheimer's disease patients.
Kogan EA; Korczyn AD; Virchovsky RG; Klimovizky SSh ; Treves TA; Neufeld MY
J Neural Transm (Vienna); 2001; 108(10):1167-73. PubMed ID: 11725819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
